Related Experiment Videos
[Neonatal screening for cystic fibrosis]
La Pediatria Medica E Chirurgica : Medical and Surgical Pediatrics
|September 1, 1994
Summary
Neonatal screening for cystic fibrosis (CF) is crucial for early intervention. The radioimmunoassay (RIA) for serum trypsin levels is the most reliable screening test, despite past attempts.
Area of Science:
- Pediatric Pulmonology
- Medical Diagnostics
- Genetics
Context:
- Cystic fibrosis (CF) is a congenital, multi-organ disease causing chronic pulmonary issues and maldigestion.
- Early symptoms of CF can be subtle, leading to delayed diagnosis, particularly with isolated lung involvement.
- Prompt treatment of pulmonary infections and maldigestion significantly improves CF patient survival.
Purpose:
- To evaluate the efficacy of neonatal screening tests for cystic fibrosis.
- To identify the most reliable screening method for early CF detection.
- To emphasize the need for effective neonatal screening protocols.
Summary:
- Neonatal screening for cystic fibrosis (CF) is essential for improving survival rates through early diagnosis and prophylaxis.
- Previous screening attempts since 1968 have lacked definitive utility.
- The radioimmunoassay (RIA) for serum trypsin levels, performed within 3-5 days of life, shows a lower frequency of false negatives and positives.
Impact:
- Highlights the critical need for a reliable neonatal screening test for cystic fibrosis.
- Suggests the RIA trypsin serum dosage as a viable option for neonatal CF screening.
- Emphasizes that early detection and intervention in CF can significantly enhance patient outcomes and longevity.